Allergan has acquired Topokine Therapeutics, a privately held, clinical-stage biotechnology company focused on developing topical medicines for fat reduction. Under the terms of the agreement, Allergan purchased Topokine Therapeutics for an up-front payment of $85 million and success-based development and sales milestones for XAF5, Topokine’s topical agent in late-stage development for the treatment of steatoblepharon.
In a Phase 2 clinical trial, XAF5 met the primary endpoint achieving statistically significant and clinically meaningful reductions in undereye bags. In January 2016, Topokine initiated a pivotal Phase 2b/3 study of XAF5.
“XAF5 has the potential to be the first topical fat reduction product for the treatment of steatoblepharon, a condition with no current therapeutic options available for patients. We look forward to continuing the outstanding development work conducted by the Topokine team to bring this innovative medical aesthetic treatment to market,” said David Nicholson, executive vice president and president of Global Brands Research & Development at Allergan.
